- Q3 2025 revenue reached ~$3.1 million, up ~4% from Q2 but flat year-over-year
- Net loss narrowed slightly to $9.5 million compared to $9.9 million in Q3 2024
- Crofelemer showed early potential to extend survival in infants with MVID, a rare intestinal disease
- No approved therapies currently exist for MVID, underscoring unmet need
- Jaguar has engaged with FDA on a potential expedited approval pathway
- Core prescription products (Mytesi, Gelclair, Canalevia-CA1) continue to anchor revenue
Jaguar Health reported its third-quarter 2025 financial results, reflecting modest revenue growth alongside ongoing investment in clinical development programs.
Financial Performance Remains Stable
The company generated approximately $3.1 million in net revenue during Q3 2025, representing a 4% increase over the prior quarter and matching revenue from the same period last year. Product revenue was driven primarily by prescription brands including Mytesi®, Gelclair®, and Canalevia®-CA1.
Despite stable revenue, Jaguar reported a net loss of $9.5 million, an improvement from $9.9 million in Q3 2024. Operating losses remained relatively consistent at approximately $7.3 million.
Expenses were mixed across categories. Research and development spending declined following the completion of a Phase 3 clinical trial, while general and administrative costs increased due to legal and compliance activities tied to financing efforts.
Crofelemer Advances in Rare Disease Research
A key highlight for the quarter was early data from an investigator-initiated proof-of-concept trial evaluating crofelemer in infants with microvillus inclusion disease (MVID), a rare and often fatal condition.
Initial findings suggest the drug may help reduce dependence on parenteral support by as much as 37%, potentially extending patient survival. However, the treatment was also associated with toxicity, and further study is required.
Importantly, there are currently no approved therapies for MVID, positioning crofelemer as a potential first-in-class option if development is successful.
Regulatory Pathway Under Exploration
Jaguar announced it has already met with the U.S. Food and Drug Administration to discuss a possible expedited approval pathway for crofelemer in MVID. The company is continuing a placebo-controlled trial to support potential regulatory submission.
Product Portfolio and Strategy
Jaguar’s commercial portfolio remains centered on gastrointestinal treatments derived from plant-based compounds. Its lead product, Mytesi® (crofelemer), is FDA-approved for HIV-related diarrhea in adults, while Canalevia®-CA1 is conditionally approved for chemotherapy-induced diarrhea in dogs.
The company continues to pursue both human and animal health indications, with a broader strategy focused on sustainably sourced, plant-derived therapeutics.
Information sourced from Jaguar Health, Inc. press release.
